Iridex Corp (IRIX) Stock Price, Quote & News

Company Profile

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems th...

Industry: Medical Devices

Sector: Healthcare

Phone: 650 940 4700

Fax: 650 940 4710

Website: www.iridex.com

Address:

1212 Terra Bella Avenue, Mountain View, United States

PeerlessSwings Mar. 28 at 9:21 PM

$GLNG $IRIX $DVS $KMB watchlist

0 · Reply

GaryBx105 Mar. 27 at 6:59 PM

$IRIX forward guidance assumes no mideast sales this year. very conservative.

1 · Reply

GaryBx105 Mar. 27 at 4:06 PM

$IRIX buying.

0 · Reply

alexpitti Mar. 26 at 8:41 PM

$IRIX middle east weakness is setting us back. hopefully cyclo g6 grows this year

0 · Reply

StocktwitsEarnings Mar. 26 at 8:28 PM

$IRIX Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$0.01 up 80.00% YoY • Reported revenue of $14.72M up 15.97% YoY • Iridex forecasts 2026 revenue between $51M and $53M, with adjusted operating expenses expected in the range of $19M to $19.5M, and expects to generate positive operating cash flow.

0 · Reply

OfficialStocktwitsUser Mar. 3 at 7:23 PM

$IRIX RSI: 52.08, MACD: 0.0188 Vol: 0.04, MA20: 1.42, MA50: 1.35 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

PortfolioProvenance Feb. 17 at 1:12 PM

$IRIX Micro-cap medtech; early-stage.

0 · Reply

BullsOnDan Feb. 17 at 8:54 AM

$IRIX Micro-cap medtech; early-stage

0 · Reply

TwoToesTrading Feb. 12 at 11:28 PM

$COSM $SPY $SPGI $IRIX $QQQ insiders

0 · Reply

MicsMugz Feb. 12 at 6:32 PM

$IRIX Let it ride.!

0 · Reply

Iridex Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 12, 2026, 4:05 PM EDT - 16 days ago

Iridex to Report Fourth Quarter and Full Year 2025 Financial Results on March 26, 2026

Feb 2, 2026, 7:00 AM EST - 7 weeks ago

Iridex Announces Plans to Relocate Headquarters

Jan 12, 2026, 7:00 AM EST - 2 months ago

Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2025

Dec 11, 2025, 7:00 AM EST - 3 months ago

Iridex Announces the Publication of an Independent Study Demonstrating Safe and Effective Retreatment with Transscleral Laser Treatment Using MicroPulse® Technology in Glaucoma Management

Dec 8, 2025, 7:00 AM EST - 3 months ago

Iridex Announces New Thermal Dynamics Study That Strengthens Clinical Foundation and Market Potential of MicroPulse® Technology and Continuous-Wave Laser for Glaucoma Treatment

Dec 5, 2025, 7:00 AM EST - 4 months ago

Iridex to Present at the Sidoti Year-End Virtual Investor Conference

Nov 11, 2025, 4:05 PM EST - 4 months ago

Iridex Reports Third Quarter 2025 Financial Results

Oct 28, 2025, 4:05 PM EDT - 5 months ago

Iridex to Report Third Quarter 2025 Financial Results on November 11, 2025

Sep 9, 2025, 4:05 PM EDT - 7 months ago

Iridex Corporation Receives Formal Notification of Nasdaq Listing Compliance

Aug 12, 2025, 4:05 PM EDT - 8 months ago

Iridex Reports Second Quarter 2025 Financial Results

Jun 24, 2025, 7:00 AM EDT - 9 months ago

Iridex Announces First Patient Enrolled in an Independent Landmark Investigator-Led UK Study Evaluating MicroPulse® Technology as an Adjunct to anti-VEGF Therapy for Diabetic Macular Edema

May 13, 2025, 4:05 PM EDT - 11 months ago

Iridex Reports First Quarter 2025 Financial Results

Apr 30, 2025, 4:05 PM EDT - 11 months ago

Iridex to Report First Quarter 2025 Financial Results on May 13, 2025

Apr 9, 2025, 4:05 PM EDT - 1 year ago

Iridex to Host Strategic Vision Call on April 16, 2025

Mar 27, 2025, 4:05 PM EDT - 1 year ago

Iridex Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 19, 2025, 9:15 AM EDT - 1 year ago

Iridex Announces Strategic Investment in the Company

Mar 14, 2025, 7:00 AM EDT - 1 year ago

Iridex Comments on Recent Stock Price Volatility

Mar 13, 2025, 5:00 PM EDT - 1 year ago

Iridex to Report Fourth Quarter and Full Year 2024 Financial Results on March 27, 2025

Dec 18, 2024, 4:05 PM EST - 1 year ago

Iridex Announces Milestone Five-Year Study Confirms the Long-Term Effectiveness and Safety of MicroPulse Transscleral Cyclophotocoagulation for Glaucoma Management

Nov 19, 2024, 8:14 AM EST - 1 year ago

Iridex Comments on Changing Glaucoma Reimbursement Landscape

Nov 4, 2024, 4:05 PM EST - 1 year ago

Iridex to Report Third Quarter 2024 Financial Results on November 12, 2024

Oct 3, 2024, 4:05 PM EDT - 1 year ago

Iridex Appoints Patrick Mercer as Chief Executive Officer

May 14, 2024, 4:05 PM EDT - 2 years ago

Iridex Reports First Quarter 2024 Financial Results

Mar 26, 2024, 4:05 PM EDT - 2 years ago

Iridex Reports Fourth Quarter and Full Year 2023 Financial Results

Mar 20, 2024, 4:05 PM EDT - 2 years ago

Iridex Schedules Fourth Quarter and Full Year 2023 Financial Results and Update on Strategic Review Process for March 26, 2024

Jan 24, 2024, 8:00 AM EST - 2 years ago

Iridex Announces First Patient Enrollment in MicroPulse® TLT Clinical Study Conducted in Collaboration with Imperial College Healthcare NHS Trust

Jan 11, 2024, 6:45 PM EST - 2 years ago

Iridex Launches New Iridex 532® and Iridex 577® Lasers in US Market Marking 35 Years of Laser Innovation in Treating Retina Disorders & Glaucoma

Dec 28, 2023, 6:00 PM EST - 2 years ago

Iridex Confirms Medicare Administrative Contractors Retired Local Coverage Determinations that Restricted Cyclophotocoagulation

Nov 27, 2023, 9:00 AM EST - 2 years ago

Iridex Corporation Announces Successful Appeal for Revision of Recent Medicare LCDs to Provide Broader Coverage of Cyclophotocoagulation

Nov 14, 2023, 4:21 PM EST - 2 years ago

Iridex Reports Third Quarter 2023 Financial Results and Business Update

Nov 13, 2023, 9:00 AM EST - 2 years ago

Iridex to Host Third Quarter Financial Results Conference Call on November 14, 2023

Oct 26, 2023, 4:22 PM EDT - 2 years ago

Iridex to Report Third Quarter Financial Results on November 14, 2023

Aug 29, 2023, 4:05 PM EDT - 2 years ago

Iridex Announces Strategic Review to Unlock Shareholder Value

Apr 27, 2023, 4:05 PM EDT - 3 years ago

Iridex to Report First Quarter Financial Results on May 11, 2023

Mar 9, 2023, 4:05 PM EST - 3 years ago

Iridex Reports Fourth Quarter and Full Year 2022 Financial Results

Mar 7, 2023, 4:05 PM EST - 3 years ago

Iridex to Present at the 35th Annual Roth Conference

Mar 2, 2023, 9:00 AM EST - 3 years ago

Iridex Introduces New Research and Showcases Five Events at the AGS Meeting

Feb 23, 2023, 4:05 PM EST - 3 years ago

Iridex to Report Fourth Quarter and Full Year 2022 Financial Results on March 9, 2023

Jan 10, 2023, 4:05 PM EST - 3 years ago

Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2022

Dec 6, 2022, 5:07 PM EST - 3 years ago

Iridex to Participate in Fireside Chat with Stifel Equity Research

Sep 29, 2022, 4:05 PM EDT - 3 years ago

Iridex Showcases its Non-Incisional Treatments for Glaucoma, Introduces Sweep Management Software, and Hosts 8 Physician Presentations at AAO 2022

Aug 18, 2022, 4:05 PM EDT - 3 years ago

Iridex to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase

Aug 15, 2022, 4:05 PM EDT - 3 years ago

Iridex Announces Second Quarter 2022 Financial Results

Aug 1, 2022, 4:05 PM EDT - 3 years ago

Iridex to Report Second Quarter 2022 Financial Results on August 15, 2022

Jun 14, 2022, 9:21 AM EDT - 4 years ago

Iridex Obtains Regulatory Clearance for Cyclo G6® Glaucoma Platform in China

May 12, 2022, 4:05 PM EDT - 4 years ago

Iridex Announces First Quarter 2022 Financial Results

Apr 28, 2022, 4:05 PM EDT - 4 years ago

Iridex to Report First Quarter 2022 Financial Results on May 12, 2022

Mar 21, 2022, 4:05 PM EDT - 4 years ago

Iridex Announces the Appointment of Beverly Huss to its Board of Directors

Mar 10, 2022, 4:05 PM EST - 4 years ago

Iridex Announces Fourth Quarter and Full Year 2021 Financial Results

PeerlessSwings Mar. 28 at 9:21 PM

$GLNG $IRIX $DVS $KMB watchlist

0 · Reply

GaryBx105 Mar. 27 at 6:59 PM

$IRIX forward guidance assumes no mideast sales this year. very conservative.

1 · Reply

GaryBx105 Mar. 27 at 4:06 PM

$IRIX buying.

0 · Reply

alexpitti Mar. 26 at 8:41 PM

$IRIX middle east weakness is setting us back. hopefully cyclo g6 grows this year

0 · Reply

StocktwitsEarnings Mar. 26 at 8:28 PM

0 · Reply

OfficialStocktwitsUser Mar. 3 at 7:23 PM

0 · Reply

PortfolioProvenance Feb. 17 at 1:12 PM

$IRIX Micro-cap medtech; early-stage.

0 · Reply

BullsOnDan Feb. 17 at 8:54 AM

$IRIX Micro-cap medtech; early-stage

0 · Reply

TwoToesTrading Feb. 12 at 11:28 PM

$COSM $SPY $SPGI $IRIX $QQQ insiders

0 · Reply

MicsMugz Feb. 12 at 6:32 PM

$IRIX Let it ride.!

0 · Reply

BillionerOfKing Feb. 10 at 6:32 PM

$IRIX Current Stock Price: $1.46 Contracts to trade: $2.5 IRIX Feb 20 2026 Call Entry: $0.01 Exit: $0.01 ROI: 65% Hold ~30 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

1 · Reply

DukeofDividends Feb. 9 at 3:17 PM

$IRIX Iris vision or medical device; requires surgeon adoption and reimbursement.

0 · Reply

StudBull Feb. 6 at 1:59 PM

$IRIX Alliance Global Partners Analyst Scott Henry initiates coverage of Iridex with a $3 price target

0 · Reply

StudBull Jan. 27 at 4:09 PM

$IRIX CFO keeps buying post pre-announcement. Another form 4 filed yesterday. I cannot imagine what that might imply for the upcoming Q4 ER/Call and the outlook for 2026

0 · Reply

10baggerPete Jan. 26 at 10:49 PM

$IRIX nice setup , a swift burst to $2.X is on deck as a likely scenario.

0 · Reply

StudBull Jan. 26 at 6:19 PM

$IRIX My imaginary A.I. friend said the following-- "Core view: treat IRIX as an emerging trend/turnaround long driven by improving fundamentals (revenue growth, positive Q4 cash flow, path to positive adjusted EBITDA) and aligned insider behavior (CFO buys)"

0 · Reply

ApolloAlerts Jan. 25 at 2:14 AM

$IRIX

0 · Reply

peepthestamp Jan. 24 at 1:20 AM

$IRIX

0 · Reply

SMARTR8 Jan. 22 at 12:23 AM

$IRIX still going 🔥🔥

1 · Reply

StudBull Jan. 21 at 8:05 PM

$IRIX CFO back again buying more stock between $1.49 and $1.53. I think that's a positive

0 · Reply

StudBull Jan. 17 at 4:33 PM

$IRIX new Form 4 filing shows CFO Dizon buying more stock yesterday (Friday 1/16) in the open market. Perhaps the strong preannounced results from earlier in the week should be viewed as a sustainable inflection versus a one time event

0 · Reply

SMARTR8 Jan. 14 at 2:54 AM

Early or not interested at all 💎 $IRIX from 0.94 👉 now 1.49 (58%+ now) $DVLT from 0.489 👉 1.50 (205%+) $BKKT from 10.55 avg 👉 20 (90%+) $LEXX from 0.506 👉 0.76 (50%+) $OSRH patience will be rewarded. All just recent trades ✅️💎🎯 I have order proof for EVERY trade I ever said I took 🤝

1 · Reply

Market Cap	17.02M
Revenue (ttm)	48.67M
Net Income (ttm)	-8.91M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-18.31%
Debt to Equity Ratio	0.79

Volume	434,500
Avg Vol	77,424
Day's Range	N/A - N/A
Shares Out	17.19M
Stochastic %K	8%
Beta	0.67
Analysts	Strong Buy
Price Target	$2.75